stockrowOptimizeRx Corp.
OPRX Healthcare Health Information Services
OptimizeRx Corp.’s revenue for fiscal 2025 (year ended December 2025) was $109.4 million, up 18.8% from fiscal 2024.
- Revenue
- −29.8%
- EPS
- −150.0%
- Free cash flow
- +89.9%
- Total debt
- −33.1%
Quarter to June 2026, against a year earlier
Follow OPRX
Alert me
OptimizeRx Corp. (OPRX) EV/Sales
As of 5 November 2026, OptimizeRx Corp. (OPRX) trades at a EV/Sales of 1.6×. Over the past ten years it has ranged from 0.8× (June 2026) to 28.6× (October 2021); the current reading is higher than 12% of that period. That is below the Health Information Services industry median of 2.6× and below the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.1× | 78.56% |
| FY2024 | 1.2× | (68.00%) |
| FY2023 | 3.7× | (0.47%) |
| FY2022 | 3.7× | (77.04%) |
| FY2021 | 16.1× | 54.11% |
| FY2020 | 10.4× | 115.33% |
| FY2019 | 4.8× | (6.50%) |
| FY2018 | 5.2× | 56.18% |
| FY2017 | 3.3× | 51.08% |
| FY2016 | 2.2× | (27.09%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 1.0× | (7.95%) |
| Mar 2026 | 1.1× | (46.32%) |
| Dec 2025 | 2.1× | (40.95%) |
| Sep 2025 | 3.6× | 42.30% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| AMWL American Well Corporation compare | 0.1× |
| DH Definitive Healthcare Corp. compare | 0.4× |
| SY So-Young International Inc. Sponsored ADR compare | 0.4× |
| LFMD LifeMD, Inc. compare | 0.5× |
| HCAT Health Catalyst, Inc. compare | 0.7× |
| SPOK Spok Holdings, Inc. compare | 1.6× |
| OPRX OptimizeRx Corp. | 1.6× |
| CTEV Claritev Corporation compare | 5.0× |
| CARL Carlsmed, Inc. compare | 5.4× |
| Health Information Services industry median | 2.6× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)